Schering-Plough International Media Advisory

BERLIN, October 19 /PRNewswire/ --

- Clinical Results with Schering-Plough's Investigational Antifungal Agent NOXAFIL(R) (posaconazole) Oral Suspension Presented at 2nd International Congress on Trends in Medical Mycology (TIMM)

- Press Briefing, Clinical Presentation and Symposium Among Featured Activities

OVERVIEW

Results of a clinical study of Schering-Plough's investigational broad-spectrum antifungal agent NOXAFIL(R) (posaconazole) oral suspension in the prevention of invasive fungal infections (IFIs) will be presented for the first time at the 2nd International Congress on Trends in Medical Mycology (TIMM) in Berlin. In addition, a press briefing/luncheon and a symposium are among featured activities.

NOXAFIL is currently awaiting approval in the European Union (EU) for use in treating certain serious invasive fungal infections in adult patients with disease that is refractory to or who are intolerant of certain commonly used antifungal agents. In July 2005, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) issued a positive opinion recommending approval of NOXAFIL for this use.

Invasive fungal infections, which can be life threatening, most often occur in people who are immunocompromised or immunosuppressed, such as organ transplant patients, cancer patients undergoing chemotherapy and/or hematopoietic stem cell transplant, or those with Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome (HIV/AIDS). In the EU, nearly 700,000 hospital patients are affected each year by life-threatening opportunistic fungal infections.

ORAL PRESENTATION Monday, 24 October, 14:06 - 14:18 hrs Session one, Clinical Mycology Berliner Congress Center, Alexanderplatz, Kuppel Saal Rooms/Main Hall.

Key clinical data on the use of NOXAFIL in the prevention of invasive fungal infections will be highlighted in the presentation, "Oral Posaconazole vs. Fluconazole for the Prophylaxis of Invasive Fungal Infections in Allogeneic Hematopoietic Stem Cell Transplant Recipients with Graft-Versus-Host Disease," by Ullmann, AJ.

KEY POSTER PRESENTATIONS Berliner Congress Center, Alexanderplatz, A floor (Ebene A). Monday, 24 October, 17:00 - 18:30 -- "Oral Posaconazole Use in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation with Graft-Versus-Host Disease: A Pharmacokinetics Analysis," by Krishna, G Tuesday, 25 October, 17:00 - 18:30 -- "In vitro Antifungal Activity Against Fusarium spp. Isolates from Skin and Nail Infections Refractory to Treatment," by Tortorano, AM For more information, please visit the TIMM Web site at www.timm2005.org. PRESS BRIEFING & LUNCHEON Tuesday, 25 October, 12:00 - 13:30 Berliner Congress Center, Alexanderplatz, Rooms A05-A06 "Severe Fungal Infections: Strategies to Maximise Patient Response"

Media are invited to attend a luncheon and press briefing sponsored by Schering-Plough on the prevention and treatment of severe fungal infections. International thought leaders and treatment experts will discuss:

-- The Patient Population Andrew Ullmann, M.D., Germany -- Emerging Pathogens and Current Challenges in Diagnosis Paul Verweij, M.D., Ph.D., Netherlands -- Diagnostic Trends and Newer Antifungal Agents David Denning, MBBS, FRCP, FRCPath, United Kingdom -- Fulfilling an Unmet Medical Need: Maximising Efficacy without Compromising Safety Raoul Herbrecht, M.D., France -- Role of Prophylaxis Against Invasive Fungal Infections Andrew Ullmann, M.D., Germany SYMPOSIUM Tuesday, 25 October, 15:30 - 17:00 Berliner Congress Center, Alexanderplatz, Kuppel Room "Unraveling the Issues in Filamentous Fungi: The Role of Newer Antifungals"

Led by an international faculty and chaired by David Denning, MBBS, FRCP, FRCPath, United Kingdom, this symposium will:

-- Describe the Epidemiologic Trends of Filamentous Fungi and Resistance Patterns Paul Verweij, M.D., Ph.D., Netherlands -- Evaluate the Role of New Antifungals as Prophylactic Therapy in Patients at High Risk for Infection Andrew Ullmann, M.D., Germany -- Review the Efficacy and Safety of Newer Treatment Options for Infections Caused by Filamentous Fungi Raoul Herbrecht, M.D., France

BERLIN, October 19 /PRNewswire/ --

Web site: http://www.schering-plough.com